drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CAR T-cell therapy: patient T cells are genetically modified to express a chimeric antigen receptor targeting a B-cell surface antigen; given as a single IV infusion after lymphodepletion to activate cytotoxic T-cell responses and eliminate malignant B cells (with expected on-target B-cell aplasia).
nci_thesaurus_concept_id
C202233
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR T Cells KITE-197
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells KITE-197 specifically recognize and kill tumor cells expressing CD19. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells. Upon binding CD19, CAR signaling (CD3ΞΆ with co-stimulation) activates and expands the T cells, inducing cytotoxic killing of malignant B cells; administered after lymphodepletion, with expected on-target B-cell aplasia.
drug_name
KITE-197
nct_id_drug_ref
NCT06079164